Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

This study is testing a three-drug combination — elotuzumab (an immunotherapy), iberdomide (a newer immune-modulating drug), and dexamethasone (a steroid) — in people with relapsed or refractory multiple myeloma (a blood cancer of plasma cells) who previously received a CAR-T cell therapy called ide-cel (idecabtagene vicleucel). **You may be eligible if...** - You have multiple myeloma that has come back or stopped responding to treatment - You have previously been treated with at least 4 prior lines of therapy, including certain standard drug classes (a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody) - You previously received ide-cel CAR-T cell therapy - You are willing and able to provide written informed consent **You may NOT be eligible if...** - You have active, uncontrolled infections or certain heart, liver, or kidney problems - You have previously been treated with iberdomide - You have active central nervous system involvement from myeloma Talk to your doctor to see if this trial is right for you.